Genome-wide characterization of lncRNAs in acute myeloid leukemia.
Lijun Lei,Siyu Xia,Dan Liu,Xiaoqing Li,Jing Feng,Yaqi Zhu,Jun Hu,Linjian Xia,Lieping Guo,Fei Chen,Hui Cheng,Ke Chen,Hanyang Hu,Xiaohua Chen,Feng Li,Shan Zhong,Nupur Mittal,Guohua Yang,Zhijian Qian,Leng Han,Chunjiang He
DOI: https://doi.org/10.1093/bib/bbx007
IF: 9.5
2018-01-01
Briefings in Bioinformatics
Abstract:Long noncoding RNAs (lncRNAs) are a large family of noncoding RNAs that play a critical role in various normal bioprocesses as well as tumorigenesis. However, the expression patterns and biological functions of lncRNAs in acute leukemia have not been well studied. Here, we performed transcriptome-wide lncRNA expression profiling of acute myeloid leukemia (AML) patient samples, along with non-leukemia control hematopoietic samples. We found that lncRNAs were differentially expressed in AML samples relative to control samples. Notably, we identified that lncRNAs upregulated in AML (relative to the control samples) are associated with a lower degree of DNA methylation and a higher ratio of being bound by transcription factors such as SP1, STAT4, ATF-2 and ELK-1 compared with those downregulated in AML. Moreover, an enrichment of H3K4me3 and a depletion of H3K27me3 were observed in upregulated lncRNAs in AML. Expression patterns of three types of lncRNAs (antisense, enhancer and intergenic lncRNAs) have previously been characterized. Of the identified lncRNAs, we found that high expression level lncRNA LOC285758 is associated with the poor prognosis in AML patients. Furthermore, we found that LOC285758 regulates proliferation of AML cell lines by enhancing the expression of HDAC2, a key factor in carcinogenesis. Collectively, our study depicts a landscape of important lncRNAs in AML and provides novel potential therapeutic targets and prognostic markers for AML treatment.